CA
NZ
UK
AU
IND
US
…
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -59.52M | -52.67M | -35.31M | -29.51M | -39.77M |
| Net income | -59.52M | -52.67M | -35.31M | -29.51M | -39.77M |
| Selling general administrative | 14.69M | 10.59M | 4.82M | 3.90M | - |
| Gross profit | -0.83M | -0.66M | -0.56M | -0.53M | -0.05M |
| Reconciled depreciation | 0.83M | 0.66M | 0.56M | 0.39M | - |
| Ebit | -59.52M | -52.37M | -35.31M | -29.51M | -39.77M |
| Ebitda | -58.69M | -51.71M | -34.75M | -29.12M | -39.72M |
| Depreciation and amortization | 0.83M | 0.66M | 0.56M | 0.39M | 0.05M |
| Operating income | -62.95M | -54.39M | -36.93M | -29.77M | -39.82M |
| Other operating expenses | 62.95M | 54.39M | 36.93M | 29.77M | 39.82M |
| Interest expense | 0.01M | 0.30M | 0.00M | - | - |
| Interest income | 3.44M | 2.01M | 1.62M | 0.25M | - |
| Net interest income | 3.43M | 1.71M | 1.62M | 0.25M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 62.12M | 54.39M | 36.93M | 29.77M | 39.77M |
| Cost of revenue | 0.83M | 0.66M | 0.56M | 0.53M | 0.05M |
| Total other income expense net | 3.43M | 1.71M | 1.62M | 0.25M | 0.05M |
| Net income from continuing ops | -59.52M | -52.67M | -35.31M | -29.51M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 62.12M | 114.91M | 35.73M | 16.00M | 154.02M |
| Other current assets | 1.79M | 2.24M | 3.89M | 2.08M | 6.06M |
| Total liab | 5.93M | 11.08M | 137.58M | 70.42M | 6.81M |
| Total stockholder equity | 56.18M | 103.83M | -101.84M | -54.42M | 147.21M |
| Other current liab | 3.94M | 7.03M | 3.66M | 2.87M | 6.20M |
| Common stock | 0.00M | 0.00M | - | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Retained earnings | -214.24M | -154.72M | -102.05M | -57.07M | -84.73M |
| Other assets | - | - | - | - | 0.00M |
| Cash | 59.05M | 110.76M | 29.88M | 11.54M | 124.66M |
| Total current liabilities | 5.92M | 10.53M | 7.29M | 5.54M | 6.20M |
| Net debt | -58.50M | -109.68M | -29.20M | -10.91M | -124.66M |
| Short term debt | 0.55M | 0.54M | 0.21M | 0.15M | - |
| Short long term debt total | 0.55M | 1.08M | 0.67M | 0.64M | - |
| Other stockholder equity | 270.42M | 258.55M | 0.21M | 2.65M | 231.90M |
| Total current assets | 60.84M | 113.00M | 33.77M | 13.62M | 153.73M |
| Short term investments | - | - | - | 81.25M | 23.01M |
| Accounts payable | 1.43M | 2.97M | 3.42M | 2.52M | - |
| Accumulated other comprehensive income | - | - | - | -0.04M | 0.03M |
| Non currrent assets other | 0.27M | 0.11M | 0.06M | 0.33M | 0.08M |
| Non current assets total | 1.28M | 1.90M | 1.97M | 2.38M | 0.29M |
| Capital lease obligations | 0.55M | 1.08M | 0.67M | 0.64M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | 15.87M | -0.25M | -1.13M | - |
| Total cashflows from investing activities | -0.05M | 15.87M | -0.25M | -1.13M | -23.38M |
| Net borrowings | 0.00M | 6.00M | 0.00M | - | - |
| Total cash from financing activities | 0.16M | 116.13M | 53.12M | 26.46M | 132.41M |
| Net income | -59.52M | -52.67M | -35.31M | -29.51M | -39.77M |
| Change in cash | -51.71M | 80.89M | 18.33M | -1.62M | 71.05M |
| Begin period cash flow | 110.76M | 29.88M | 11.54M | 13.16M | 53.61M |
| End period cash flow | 59.05M | 110.76M | 29.88M | 11.54M | 124.66M |
| Total cash from operating activities | -51.83M | -51.12M | -34.55M | -26.95M | -37.98M |
| Issuance of capital stock | 0.00M | 58.91M | 53.85M | 27.84M | - |
| Depreciation | 0.83M | 0.66M | 0.56M | 0.39M | 0.05M |
| Other cashflows from investing activities | - | - | - | -44.10M | - |
| Other cashflows from financing activities | -0.04M | 51.22M | 53.06M | 26.12M | - |
| Capital expenditures | 0.05M | 0.05M | 0.25M | 1.13M | 0.20M |
| Change in working capital | -4.78M | -3.95M | 0.01M | 2.12M | -2.80M |
| Stock based compensation | 11.63M | 4.53M | 0.20M | 0.05M | - |
| Other non cash items | 0.01M | 0.32M | - | - | 4.54M |
| Free cash flow | -51.87M | -51.17M | -34.79M | -28.09M | -38.18M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| OKUR OnKure Therapeutics, Inc. |
0.34 13.47% |
2.87 | - | - | - | 0.70 | 0.03 |
| NVO Novo Nordisk A/S |
0.01 0.02% |
40.31 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
4.59 0.85% |
547.09 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
1.45 0.16% |
904.35 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
6707 Winchester Circle, Boulder, CO, United States, 80301
720-307-2892
45
| Name | Title | Year Born |
|---|---|---|
| Dr. Nicholas A. Saccomano Ph.D. | President, CEO & Director | 1959 |
| Mr. Jason A. Leverone CPA | Chief Financial Officer | 1974 |
| Dr. Isaac Manke Ph.D. | Senior VP of Business Development & Director | 1977 |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer | 1973 |
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer | 1969 |
| Mr. Rogan P. Nunn J.D. | General Counsel & Secretary | NA |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery | NA |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK & Clinical Pharmacology | NA |
| Dr. Mark L. Boys Ph.D. | Senior Vice President of Discovery Chemistry | NA |
| Ms. Roberta Alton | Senior Vice President of Clinical Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...